Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||FLT3/CD3 Fabsc antibody + Quizartinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|FLT3/CD3 Fabsc antibody||FLT3/CD3 Fabsc antibody is a Fabsc-format bi-specific antibody that targets both FLT3 and CD3, potentially resulting in induction of T-cell activation and antibody-dependent cellular cytotoxicity against FLT3-expressing tumor cells (PMID: 25578618).|
|Quizartinib||Vanflyta|AC220||FLT3 Inhibitor 55 KIT Inhibitor 51 PDGFR-alpha Inhibitor 9 RET Inhibitor 39||Vanflyta (Quizartinib) targets both wild-type and mutant FLT3 containing activating internal tandem duplications, as well as PDGFRA, RET, and KIT, which may induce apoptosis and inhibit tumor growth (PMID: 19654408, PMID: 23497317).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 exon 14 ins FLT3 LOH||acute myeloid leukemia||sensitive||FLT3/CD3 Fabsc antibody + Quizartinib||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with the combination of Quizartinib (AC220) and an Fabsc FLT3/CD3 bi-specific antibody resulted in increased cytotoxicity over either agent alone in an acute myeloid leukemia cell line and patient-derived xenograft (PDX)-derived AML cells with a FLT3-ITD mutation and FLT3 loss of heterozygosity, leading to near complete eradication of AML cells in culture (PMID: 28895560).||28895560|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|